2022
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
Mattocks KM, Moore DT, Wischik DL, Lazar CM, Rosen MI. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic. Journal Of Substance Use And Addiction Treatment 2022, 139: 108777. PMID: 35346533, PMCID: PMC8949846, DOI: 10.1016/j.jsat.2022.108777.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Health AffairsVA Medical CenterTreatment of OUDVirtual visitsSerious public health issueOpioid addiction epidemicUse of telemedicineCOVID-19Public health issuePotential study participantsHarm reduction approachPatient's autonomous decisionBuprenorphine treatmentOUD treatmentChronic painCOVID-19 transmissionOUD careVA providersVA cliniciansMedical CenterOpioid addictionVHA providersUse disordersAddiction epidemic
2021
The intertwined expansion of telehealth and buprenorphine access from a prescriber hub
Moore DT, Wischik DL, Lazar CM, Vassallo GG, Rosen MI. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub. Preventive Medicine 2021, 152: 106603. PMID: 33974959, DOI: 10.1016/j.ypmed.2021.106603.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCOVID-19HumansOpiate Substitution TreatmentOpioid-Related DisordersPandemicsSARS-CoV-2Telemedicine